Innovent Biologics (HKEX: 01801) and Eli Lilly and Company (NYSE: LLY) have entered a distribution and promotion agreement granting Innovent sole commercialization rights for abemaciclib (Verzenios) in mainland China. Lilly retains its Marketing Authorization Holder status and remains responsible for manufacturing, supply, and ongoing development. Financial terms were not disclosed.
Under the agreement, Innovent assumes responsibility for importation, marketing, distribution, and promotion of the approved CDK4/6 inhibitor across its multiple China-approved indications — including adjuvant HR-positive, HER2-negative early breast cancer and locally advanced or metastatic settings — while Lilly maintains full regulatory ownership and product supply control. This split preserves Lilly's regulatory accountability without requiring it to maintain a dedicated China oncology sales force.
Abemaciclib inhibits cyclin-dependent kinases 4 and 6, blocking cell cycle progression in HR-positive breast cancer cells. It was the first CDK4/6 inhibitor included in China's National Reimbursement Drug List (NRDL) Class B in 2021, and renewed its listing in 2025 with full coverage across both early and advanced breast cancer indications — including a combination with imlunestrant for ESR1-mutated disease. Among CDK4/6 inhibitors, abemaciclib holds a clinical differentiation argument in the adjuvant setting based on monarchE data, a competitive moat that domestic entrants currently lack. Pfizer's palbociclib (Ibrance) and Novartis's ribociclib (Kisqali) are also NRDL-listed competitors, as are several domestic CDK4/6 entrants added in 2025.